The nation of Zimbabwe has declined a major US health deal valued at 367 million US dollars (272 million pounds) spanning five years because of Washington's insistence on sensitive biological samples.
This rejection came to light following a official document dated December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the agreement was "unbalanced".
A government spokesman later explained that the US was requesting genetic material for scientific study and commercial purposes while was not willing to guarantee the resulting advantages from future vaccines.
"We will now turn to the difficult and regrettable process of scaling back our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had provided more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for more talks to secure a agreement acceptable to both sides so the country's vital HIV treatment initiative can be sustained.
Broader Context
This rejection follows a similar situation in neighbouring Kenya, where a court suspended a related health funding agreement following legal challenges were raised about the safety of citizens' medical information.
Since returning to office recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had administered aid for the US government, but Trump stated its spending was "inefficient" and his government was seeking direct bilateral deals to boost openness and accountability.
According to statements, Sixteen nations in Africa have to date signed similar health pacts, constituting more than $18.3bn of fresh investment.
Details of the Declined Agreement
The money for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration could have provided significant advantages for Zimbabwean communities, especially the 1.2 million presently receiving antiretroviral therapy via US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to share its genetic material and health information over an extended period, without any equivalent guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that shared data," he stated.
"In essence, our country would supply the basic resources for scientific discovery with no assurance that the final treatments would be accessible to our population should a future health crisis arise."
National Interest and International Frameworks
He also noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were undermining systems previously established via the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system designed to manage future global health emergencies.
"This system is designed to guarantee that when a nation contributes its data, the resulting advantages – including medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to create them."
The government's concerns regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We are open to further discussions with our US partners on how future collaboration might be arranged in a way that honours the sovereignty and dignity of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the government's concerns, but urged that talks need to persist given that much of the nation's HIV programmes depended on foreign aid.
"In cases where technical issues exist, including those relating to data governance or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," the group added.
The halted deal highlights the ongoing tensions between accepting vital international aid and safeguarding national sovereignty in an increasingly data-driven world.